Theseus Pharmaceuticals Statistics
Total Valuation
Avanos Medical has a market cap or net worth of $498.36 million. The enterprise value is $545.36 million.
Important Dates
The last earnings date was Tuesday, August 5, 2025, before market open.
| Earnings Date | Aug 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Avanos Medical has 46.40 million shares outstanding. The number of shares has decreased by -1.07% in one year.
| Current Share Class | 46.40M |
| Shares Outstanding | 46.40M |
| Shares Change (YoY) | -1.07% |
| Shares Change (QoQ) | -1.07% |
| Owned by Insiders (%) | 1.80% |
| Owned by Institutions (%) | 93.80% |
| Float | 45.36M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 11.67 |
| PS Ratio | 0.71 |
| Forward PS | 0.95 |
| PB Ratio | 0.64 |
| P/TBV Ratio | 1.72 |
| P/FCF Ratio | 5.67 |
| P/OCF Ratio | 4.39 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 6.18, with an EV/FCF ratio of 6.20.
| EV / Earnings | n/a |
| EV / Sales | 0.79 |
| EV / EBITDA | 6.18 |
| EV / EBIT | 11.88 |
| EV / FCF | 6.20 |
Financial Position
The company has a current ratio of 2.64, with a Debt / Equity ratio of 0.18.
| Current Ratio | 2.64 |
| Quick Ratio | 1.49 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | 1.35 |
| Debt / FCF | 1.56 |
| Interest Coverage | 4.54 |
Financial Efficiency
Return on equity (ROE) is -46.17% and return on invested capital (ROIC) is 2.44%.
| Return on Equity (ROE) | -46.17% |
| Return on Assets (ROA) | 2.13% |
| Return on Invested Capital (ROIC) | 2.44% |
| Return on Capital Employed (ROCE) | 5.08% |
| Revenue Per Employee | $310,956 |
| Profits Per Employee | -$207,993 |
| Employee Count | 2,227 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 2.09 |
Taxes
| Income Tax | -15.90M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -53.18% in the last 52 weeks. The beta is 1.12, so Avanos Medical's price volatility has been higher than the market average.
| Beta (5Y) | 1.12 |
| 52-Week Price Change | -53.18% |
| 50-Day Moving Average | 11.97 |
| 200-Day Moving Average | 15.00 |
| Relative Strength Index (RSI) | 40.72 |
| Average Volume (20 Days) | 599,158 |
Short Selling Information
The latest short interest is 1.51 million, so 3.25% of the outstanding shares have been sold short.
| Short Interest | 1.51M |
| Short Previous Month | 1.67M |
| Short % of Shares Out | 3.25% |
| Short % of Float | 3.33% |
| Short Ratio (days to cover) | 3.31 |
Income Statement
In the last 12 months, Avanos Medical had revenue of $692.50 million and -$463.20 million in losses. Loss per share was -$10.06.
| Revenue | 692.50M |
| Gross Profit | 372.80M |
| Operating Income | 45.90M |
| Pretax Income | 14.70M |
| Net Income | -463.20M |
| EBITDA | 88.30M |
| EBIT | 45.90M |
| Loss Per Share | -$10.06 |
Full Income StatementBalance Sheet
The company has $90.30 million in cash and $137.30 million in debt, giving a net cash position of -$47.00 million or -$1.01 per share.
| Cash & Cash Equivalents | 90.30M |
| Total Debt | 137.30M |
| Net Cash | -47.00M |
| Net Cash Per Share | -$1.01 |
| Equity (Book Value) | 776.30M |
| Book Value Per Share | 16.76 |
| Working Capital | 221.40M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $113.40 million and capital expenditures -$25.50 million, giving a free cash flow of $87.90 million.
| Operating Cash Flow | 113.40M |
| Capital Expenditures | -25.50M |
| Free Cash Flow | 87.90M |
| FCF Per Share | $1.89 |
Full Cash Flow StatementMargins
Gross margin is 53.83%, with operating and profit margins of 6.63% and -66.89%.
| Gross Margin | 53.83% |
| Operating Margin | 6.63% |
| Pretax Margin | -68.91% |
| Profit Margin | -66.89% |
| EBITDA Margin | 12.75% |
| EBIT Margin | 6.63% |
| FCF Margin | 12.69% |
Dividends & Yields
Avanos Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.07% |
| Shareholder Yield | 1.07% |
| Earnings Yield | -92.94% |
| FCF Yield | 17.64% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Avanos Medical has an Altman Z-Score of 1.8 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.8 |
| Piotroski F-Score | 6 |
